Tags

Type your tag names separated by a space and hit enter

Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation.
J Int Med Res. 2020 May; 48(5):300060520920438.JI

Abstract

BACKGROUND

Mesenchymal stem cells (MSCs) may be used to treat steroid-refractory graft versus host disease (GVHD). However, the effects of MSCs in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) have not been confirmed in randomized studies.

METHODS

We conducted a randomized clinical study to investigate the effects of pre-infusion (1 × 106 cells/kg) MSCs on hematopoietic recovery, Epstein-Barr and cytomegalovirus infection, GVHD, and relapse in patients undergoing haplo-PBSCT. Fifty patients with acute leukemia or myelodysplastic syndrome were randomly divided into an MSC group administered 1 × 106 MSCs/kg 4 to 6 hours before infusion of peripheral stem cells and a control group without MSCs.

RESULTS

Mean platelet engraftment time was significantly faster in the MSC compared with the control group (12.28 vs 13.29 days). The mean neutrophil engraftment time was comparable in both groups (10.76 ± 2.40 vs. 10.29 ± 1.72 days). Grade II or above acute GVHD was significantly decreased in the MSC compared with the control group (12% vs. 36%). There were no significant differences in relapse rate or overall survival between the groups.

CONCLUSION

These results suggest that pre-infusion single-dose MSCs promote platelet engraftment and decrease severe acute GVHD without increasing relapse rate.

Authors+Show Affiliations

Department of Hematology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.Department of Hematology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.Department of Hematology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32363972

Citation

Wang, Xiaoning, et al. "Pre-infusion Single-dose Mesenchymal Stem Cells Promote Platelet Engraftment and Decrease Severe Acute Graft Versus Host Disease Without Relapse in Haploidentical Peripheral Blood Stem Cell Transplantation." The Journal of International Medical Research, vol. 48, no. 5, 2020, p. 300060520920438.
Wang X, Zhang M, He P. Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation. J Int Med Res. 2020;48(5):300060520920438.
Wang, X., Zhang, M., & He, P. (2020). Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation. The Journal of International Medical Research, 48(5), 300060520920438. https://doi.org/10.1177/0300060520920438
Wang X, Zhang M, He P. Pre-infusion Single-dose Mesenchymal Stem Cells Promote Platelet Engraftment and Decrease Severe Acute Graft Versus Host Disease Without Relapse in Haploidentical Peripheral Blood Stem Cell Transplantation. J Int Med Res. 2020;48(5):300060520920438. PubMed PMID: 32363972.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pre-infusion single-dose mesenchymal stem cells promote platelet engraftment and decrease severe acute graft versus host disease without relapse in haploidentical peripheral blood stem cell transplantation. AU - Wang,Xiaoning, AU - Zhang,Mei, AU - He,Pengcheng, PY - 2020/5/5/entrez PY - 2020/5/5/pubmed PY - 2020/5/5/medline KW - Mesenchymal stem cell KW - acute leukemia KW - graft versus host disease KW - haploidentical peripheral blood stem cell transplantation KW - myelodysplastic syndrome KW - platelet engraftment SP - 300060520920438 EP - 300060520920438 JF - The Journal of international medical research JO - J. Int. Med. Res. VL - 48 IS - 5 N2 - BACKGROUND: Mesenchymal stem cells (MSCs) may be used to treat steroid-refractory graft versus host disease (GVHD). However, the effects of MSCs in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) have not been confirmed in randomized studies. METHODS: We conducted a randomized clinical study to investigate the effects of pre-infusion (1 × 106 cells/kg) MSCs on hematopoietic recovery, Epstein-Barr and cytomegalovirus infection, GVHD, and relapse in patients undergoing haplo-PBSCT. Fifty patients with acute leukemia or myelodysplastic syndrome were randomly divided into an MSC group administered 1 × 106 MSCs/kg 4 to 6 hours before infusion of peripheral stem cells and a control group without MSCs. RESULTS: Mean platelet engraftment time was significantly faster in the MSC compared with the control group (12.28 vs 13.29 days). The mean neutrophil engraftment time was comparable in both groups (10.76 ± 2.40 vs. 10.29 ± 1.72 days). Grade II or above acute GVHD was significantly decreased in the MSC compared with the control group (12% vs. 36%). There were no significant differences in relapse rate or overall survival between the groups. CONCLUSION: These results suggest that pre-infusion single-dose MSCs promote platelet engraftment and decrease severe acute GVHD without increasing relapse rate. SN - 1473-2300 UR - https://www.unboundmedicine.com/medline/citation/32363972/Pre-infusion_single-dose_mesenchymal_stem_cells_promote_platelet_engraftment_and_decrease_severe_acute_graft_versus_host_disease_without_relapse_in_haploidentical_peripheral_blood_stem_cell_transplantation L2 - https://journals.sagepub.com/doi/10.1177/0300060520920438?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.